The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

H1 Blog

JULY 30, 2024

This effort seeks to provide the pharmaceutical industry with more accurate representation of patient populations, thereby enhancing the safety and efficacy for prescription drugs and medical devices. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.”

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

JULY 5, 2023

The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within a trial population helps ensure the safety and efficacy of drugs that reach the market. African Americans).

Clinical Trials 52

Clinical Trials Drugs Trials Drug Development 52

Alta Sciences

APRIL 5, 2024

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

Drug Development 52

Drug Development Pharma Companies Marketing Drugs 52

PPD

JULY 13, 2023

At the beginning of 2023, the PPD clinical research business of Thermo Fisher Scientific surveyed 120 drug developers across the pharmaceutical, biopharmaceutical and biotechnology sectors (referred to collectively as “pharma”) to learn more about sponsors’ current needs for site and patient recruitment services.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Clinical Research 52

DrugBaron

JANUARY 31, 2024

Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.

Pharma R&D 165

Pharma R&D Science Small Molecule Drugs 165

Drug Target Review

MARCH 15, 2024

Cultural differences between the UK and mainland Europe were still quite different then but we settled in Southampton and I later went to University in Brighton, studied for a D.Phil, and found a job at a Pharma company. She has held leadership positions in Project Management, Technical Operations, and Business Development.

Organic Chemistry 59

Organic Chemistry Pharma Companies Clinical Trials Pharmaceuticals 59

PerkinElmer

FEBRUARY 18, 2021

Industry leaders reveal how high throughput screening is changing in R&D What do you think are the major trends in drug discovery R&D? That is not what PerkinElmer found in a comprehensive survey of leaders at the top 20 Pharma, ranked for R&D spending. Top 10 trends in pre-clinical drug discovery at top 20 Pharma 1.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Predictive Oncology

FEBRUARY 7, 2023

NEW YORK – Predictive Oncology wants to ink more partnerships with biopharmaceutical companies and demonstrate the ability of its commercially available PEDAL platform to provide early insights that sponsors can use to prioritize drugs for development and identify biomarker-informed indications.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 52

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

OCTOBER 20, 2020

MD Anderson has historically collaborated with biotechs and pharma companies to conduct cancer therapy research. Through investment from the Cancer Focus Fund and the support of MD Anderson, we hope to advance worthwhile new treatments past the traditional hurdles in the drug development process.” . Source link.

Clinical Trials 52

Clinical Trials Therapies Pharma Companies Trials 52

The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

DrugBank

JUNE 27, 2024

Drug repurposing is an approach that, while not new, has become popular in the last decade.   One of the most exciting prospects of drug repurposing is its potential to tackle "undruggable" targets—proteins or molecules that traditional drugs can't easily bind to.

Drugs 71

Drugs Pharma Companies Clinical Trials Computational Chemistry 71

DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules. But it has its limitations too.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

The Connected Lab

APRIL 8, 2020

Prescription drugs have the ability to transform a patient’s life and provides them the opportunity to rid a devastating illness, making the development and approval of these medications urgent and necessary. However, over the last 10 years the path leading to drug approval has become more complicated and expensive.

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

DrugBaron

OCTOBER 17, 2022

Of course, Occam’s razor suggests the simplest explanation is likely to be right: the drug just doesn’t work well enough – but many millions are often burnt before the inevitable conclusion is reached. In practice, this looks much more like a traditional pharma company than a biotech. The wrong dose? The wrong end-point?

Pharma Companies 100

Pharma Companies Pharmaceuticals Drug Development Production 100

Agency IQ

JULY 12, 2024

In regulation, intended use is defined at 21 CFR 201.128 for drugs and 21 CFR 801.4 for medical devices as “the objective intent of the persons legally responsible for the labeling of” drugs of devices. For drug products, the FDA regulates both product labeling ( 21 CFR 201 ) and promotional labeling ( 21 CFR 202 ).

FDA 40

FDA Regulations Production Science 40

Drug Target Review

MAY 23, 2023

9 Academic scientists researching natural products often struggle with the pitfalls of drug development. Since methodologies such as combinatorial chemistry have not had the anticipated success rates, drug discovery now depends on new, natural compounds. Their combined action is needed to treat complex diseases such as IBD.

Drugs 75

Drugs Small Molecule Production Disease 75

Metabolite Tales Blog

DECEMBER 19, 2023

Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group A Metabolite Bioanalysis Working Group comprised of experts from 14 different pharma companies have proposed recommendations around best practice in metabolite bioanalysis during drug development.

Pharma Companies 52

Pharma Companies Drug Development Compliance Trials 52

Dark Matter Blog

JUNE 21, 2023

As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you’re charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you would be wrong. This latter course is Arrakis’ strategy.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Altus Drug Development

JUNE 28, 2022

Value-added medicines are novel drug products created to provide improvements for patients that can’t be achieved using traditional therapeutic methods. The purpose of research and development in the pharmaceutical industry is the incremental innovation of medicinal products and treatments. What is a value-added medicine?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52

The Pharma Data

OCTOBER 30, 2020

With an average of only 5 – 10 projects awarded to EU companies by the FDA each year, this development represents a landmark achievement for RCPE and reflects the potential impact of these projects within the global pharma industry.

FDA 52

FDA Engineering Pharma Companies Pharmaceuticals 52

Vial

FEBRUARY 19, 2024

The neat thing about it, it was an oral drug that can inhibit a specific receptor on the B cells that are causing different types of leukemia and lymphoma. We can link small molecule drugs to a payload that would enter in the cell and kill it. The current ADCs, they’re all great drugs, but yet have not delivered on the promise.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Pharma Data

NOVEMBER 10, 2020

Yohan Tessier, Vice President of Commercial Operations & Strategic Development at Mispro, explained that this is critical in expediting their clients’ time to market. We’re seeing a trend in drug development towards super complex and highly-targeted compounds, which requires researchers to conduct a number of preclinical studies.

Marketing 52

Marketing Science Pharma Companies Research 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 118

Therapies Virus DNA Clinical Trials 118

The Pharma Data

DECEMBER 30, 2020

Food and Drug Administration (FDA), noted in December 2020 that he expected the pandemic could “effectively” be ended in 2021 with the launch of the Pfizer-BioNTech and Moderna vaccines. Then, in July, after analyzing completed data and with talks with the FDA, they decided they were going to pursue regulatory approval for the drug.

Vaccine 52

Vaccine FDA Trials Therapies 52

Drug & Device Law

SEPTEMBER 1, 2023

We observed oral argument the other day in a case that could have a significant impact on potential liability under California tort law for pharma companies and all other innovators. That is the group of drugs that the plaintiffs allegedly used and that allegedly caused harmful side effects. In Gilead v. Superior Court , No.

Production 64

Production Marketing Drugs Pharma Companies 64